Moss CURRICULUM VITAE amnesia

Document Sample
Moss CURRICULUM VITAE amnesia Powered By Docstoc
					                                    CURRICULUM VITAE
                                         May 2006

Name:      Donald E. Moss
Born:     December 9, 1944
Address:   Department of Psychology
           University of Texas at El Paso
           El Paso, Texas 79968-0553
Telephone: (915) 747-5551 (Office) (915) 532-5017 (Home) E-Mail: dmoss@utep.edu
Languages: English and Spanish
                                          Education

B.S. - 1966 Colorado State University, Psychology.
M.S. - 1968 Colorado State University, Experimental Psychology
Ph.D. - 1973 Colorado State University, Physiological Psychology (Psychobiochemistry).
Postdoc. 1973-75 University of California at San Diego, Sloan
           Foundation Fellow in Neurosciences.

                                            Positions

Professor, Department of Psychology, University of Texas at El Paso
       (Asst. Prof. 1975-1978, Assoc. Prof. 1978-1985).

Clinical Associate Professor, Department of Psychiatry, Texas Tech University Health Sciences
        Center, School of Medicine, El Paso, Texas (1995- present).

Chairman of the Graduate Faculty of the University of Texas at El Paso, 1984-1988.

Director, University of Texas at El Paso Alzheimer's Disease Research Project, September 1985 to
       present (A multidisciplinary project funded by the Meadows Foundation of Dallas Texas,
       $250,000 June 1986 through August 1988).

Director, Minority Biomedical Research Support Program at the University of Texas at El Paso,
       June 1980 through November 1984. This is a multiproject research program involving the
       Departments of Chemistry, Biological Sciences, and Psychology. Between 1980 and 1984,
       this program supported 9 research projects awarded $2,318,959.

Assistant Dean of the Graduate School and Director of Research for the University of Texas at El
       Paso. June 1980-August 1981 (Interim Position).

Sloan Foundation Postdoctoral Fellow in the Neurosciences, University of California at San Diego.
       1973-1975 (with J. A. Deutsch).

Research and Development Coordinating Officer, United States Army Human Engineering
       Laboratories, Aberdeen Proving Ground, Maryland. 1968-1969.
D.E. Moss                         CURRICULUM VITAE                                 page 2

                                 Special Professional Activities

Borlongan, C. and Moss, D.E. U.S. Patent Application, Serial Number 10/218,893 Entitled
       "Methods of Attenuating Cognitive Deficits with Sulfonyl Fluorides", filed 08/14/2002,
       pending.

Moss, D.E., Sponsor of an application for an Investigational New Drug (IND) exemption entitled
      "Methanesulfonyl Fluoride as a Therapeutic Drug in the Treatment of Alzheimer's Disease",
      IND #29,455 (inactive).

Moss, D.E. U.S. Patent Serial No. 5,798,392; "Sulfonyl Fluorides for the Treatment of
      Alzheimer's Disease", Issued August 25, 1998 [Australian No. 731775; European Union
      No. 921790 (France, Germany, Italy, and United Kingdom (issued)); Canada No. 2,264,582
      (pending)].

Moss, D.E., Appointed by the Governor of Texas to the Texas Council on Alzheimer's Disease and
      Related Disorders: Chairman of the Council 1989 - 1992, Chairman, Medical Research
      Committee 1987 - 1989.


                                 Other Professional Activities

Editor: Leaves of Grass: An International Newsletter on Marijuana
   Research (1989-1991).
Editorial Board Member: Neurobiology of Aging (l980-1986)
Invited Reviewer for manuscripts submitted to:
   Neurobiology of Aging (1986-present)
   Pharmacology Biochemistry and Behavior (1974-present)
   Physiology and Behavior (1977-present)
   Biological Psychiatry (1995-present)
   Life Science (1987-present)
Professional Affiliations:
      Society for Neuroscience
      International Cannabinoid Study Group (Charter Member)
      International Behavioral Neuroscience Society
          (Founding Member)
      Golden Key National Honorary Society (Honorary Member)

                                      Honors and Awards

1985 Award for Outstanding Psychological Research, presented by the El Paso Psychological
      Association.
D.E. Moss                        CURRICULUM VITAE                                page 3
1991 Received the Distinguished Achievement Award in Research at the University of Texas at El
      Paso.

1996 Received the Distinguished Achievement Award in Teaching Excellence at the University of
      Texas at El Paso.


                                     Scholarly Publications

Carcoba, L.M., Santiago, M., Moss, D.E., and Cabeza, R. In utero Methanesulfonyl fluoride
      differentially affects learning and maze performance in the absence of long-lasting
      cholinergic changes in the adult rat. Pharmacology Biochemistry and Behavior, in press,
      2007.

Byers, D.M., Irwin, L.N., Moss, D.E., Sumaya, I.C., and Hohmann, C.F. Prenatal exposure to the
       acetylcholinesterase inhibitor methanesulfonyl fluoride alters forebrain morphology and
       gene expression. Brain Res Dev Brain Res. 2005 Aug 8;158(1-2):13-22.

Borlongan, C.V., Sumaya, I., and Moss, D.E. Methanesulfonyl fluoride, an acetylcholinesterase
       inhibitor, attenuates cognitive deficits in ischemic rats. Brain Research, 2005, Mar
       15;1038(1):50-8..

Sumaya, I.C., Byers, D.M., Irwin, L.N., Del Val, S., and Moss, D.E. Circadian-dependent effect of
      melatonin on dopaminergic D2 antagonist-induced hypokinesia and agonist-induced
      stereotypies in rats. Pharmacology Biochemistry and Behavior, 2004, 78, 727-733.

Borlongan, C.V., Sumaya, I., Moss, D.E., Kumazai, M., Sakurai, T., Hida, H., and Nishino, H.
       Melatonin-secreting pineal gland: A novel tissue source for neural transplantation therapy
       in stroke. Cell Transplantation, 2003, 12, 225-234.

Sumaya, I.C., Rienzi, B.M., Deegan, J.F., and Moss, D.E. Bright light treatment decreases
      depression in institutionalized older adults: A placebo controlled cross-over study.
      Journal of Gerontology: MEDICAL SCIENCES, 2001, 56A (6), M356-M360.

Hagan, M.M., Tomaka, J., & Moss, D. E. Relation of dieting in college and high-school students
       to symptoms associated with semistarvation. Journal of Health Psychology, 5 (1), 2000,
       7-15.

Hagan, M.M., Whitworth, R.H., & Moss, D.E. Semistarvation-associated eating behaviors
       among college binge-eaters: Preliminary description and assessment scale. Behavioral
       Medicine, 25(3), 125-133, 1999.

Kobayashi, H., Nakano, T., Moss, D.E., and Tadahiko, S. Effects of a central anticholinesterase,
      methanesulfonyl fluoride on the cerebral cholinergic system and behavior in mice:
D.E. Moss                      CURRICULUM VITAE                               page 4
      Comparison with an organophosphate DDVP. Journal of Health Science, 45(4), 191-202,
      1999.

Moss, D.E., Berlanga, P., Hagan, M.M., Sandoval, H., and Ishida, C. Methanesulfonyl fluoride
      (MSF): A double blind, placebo controlled study of safety and efficacy in the treatment of
      senile dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 13(1),
      20-25,1999.

Hagan, M.M., Castañeda, E., Fleming, S.M., Sumaya-Smith, I.C., Galloway, J., and Moss, D.E.
       The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo:
       Implications for limbic function in binge-eating behavior. Brain Research 805, 20-28,
       1998.

Hagan, M.M., Holguin, F.D., Cabello, C.E., Hanscom, D.R., and Moss, D.E. Combined naloxone
       and fluoxetine on deprivation-induced binge-eating of palatable foods in rats.
       Pharmacology Biochemistry and Behavior 58, 1103-1107, 1997.

Hagan, M.M. and Moss, D.E. Persistence of binge-eating patterns after a history of restriction with
       intermittent bouts of refeeding on palatable foods in rats: Implications for bulimia nervosa.
       International Journal of Eating Disorders 22, 411-420, 1997.

Moss, D.E. and Castañeda, E. Automated methods of measuring gnawing behaviors. In: Motor
      Activity and Movement Disorders: Research Issues and Applications, P.R. Sanberg, K.P.
      Ossenkopp, and M. Kavaliers (Eds.), Humana Press, New York, 1996. pp. 175-194.

Pacheco, G., Palacios-Esquivel, R., and Moss, D.E. Cholinesterase inhibitors proposed for treating
      dementia in Alzheimer's disease: Selectivity toward human brain acetylcholin-esterase
      compared to butyrylcholinesterase. Journal of Pharmacology and Experimental
      Therapeutics 274, 767-770, 1995.

Hagan, M.M. and Moss, D.E. Effect of peptide YY (PYY) on food associated conflict. Physiology
       and Behavior 58, 731-735, 1995.

Hagan, M.M. and Moss, D.E. Differential effects of Tyr-MIF-1, MIF-1, and naloxone on peptide
       YY-induced hyperphagia. Peptides 15, 243-245, 1994.

Malin, D.H., Plotner, R.E., Radulescu, S.J., Perebee, R.N., Lake, J.R., Negrete, P.G., Schaefer, P.J.,
       Crothers, M.K., and Moss, D.E. Chronic methanesulfonyl fluoride enhances one- trial per
       day reward learning in aged rats. Neurobiology of Aging 14, 393-395, 1993.

Hagan, M.M. and Moss, D.E. Suppression of peptide YY-induced hyperphagia by terbutaline.
       Pharmacology Biochemistry and Behavior 46, 679-681, 1993.
D.E. Moss                           CURRICULUM VITAE                             page 5
Palacios-Esquivel, R., Pacheco, G, and Moss, D.E. Methanesulfonyl fluoride (MSF) blocks
       scopolamine-induced amnesia in rats. Neurobiology of Aging 14, 93-96, 1993.

Hagan, M.M. and Moss, D.E. The effect of naloxone and antidepressants on hyperphagia produced
       by peptide YY. Pharmacology Biochemistry and Behavior 45 941-944, 1993.

Rogers, J., Schultz, J., Brachova, L., Lue, L.-F., Webster, S., Bradt, B., Cooper, N.R., and Moss,
       D.E. Complement activation and b-amyloid-mediated neurotoxicity in Alzheimer's disease.
        Research in Immunology 143, 624-630, 1992.

Moss, D.E., Gutierrez, Y.R., Perez, R.G., and Kobayashi, H. Simple spectrophotometric assay for
      calcium activated neutral proteases (Calpains). Pharmacology Biochemistry and Behavior
      39, 495-497, 1991.

Castañeda, E., Moss, D.E., Oddie, S.D., and Whishaw, I. THC does not affect striatal dopamine
       release: microdialysis in freely moving rats. Pharmacology Biochemistry and Behavior
       40, 587-591, 1991.

Hagan, M.M. and Moss, D.E. An animal model of bulimia and anorexia nervosa: opioid
       sensitivity to fasting episodes. Pharmacology Biochemistry and Behavior 39, 421-422,
       1991.

Malin, D.H., Toups, P.J., Osgood, L.D., Fowler, D.E., Hunter, C.L., Arcangeli, K.R., and Moss,
       D.E. Methanesulfonyl fluoride enhances one-trial learning in mid-aged rats. Neurobiology
       of Aging 12, 181-183, 1991.

Moss, D.E., Manderscheid, P.Z., Montgomery, S.P., Norman, A.B., and Sanberg, P.R. Nicotine
      and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and
      other motor disorders. Life Sciences 44, 1521-1525, 1989.

Moss, D.E., Kobayashi, H., Pacheco, G., Palacios, R., and Perez, R.G. Methanesulfonyl fluoride:
      A CNS selective cholinesterase inhibitor. In: Current Research in Alzheimer Therapy:
      Cholinesterase Inhibitors, E. Giacobini and R. Becker (Eds.), Taylor and Francis, New
      York, 1988. pp. 305-314.

Moss, D.E., Manderscheid, P.Z., Kobayashi, H., and Montgomery, S.P. Evidence for the nicotinic
      hypothesis of cannabinoid action within the central nervous system: Extrapyramidal motor
      behaviors. In: Marihuana '87, G. Chesher, P. Consroe, and R. Musty (Eds.), National
      Campaign Against Drug Abuse, Canberra, Australia, 1988. pp. 359-364.

Chang, C.A., Lin, G.-C., and Moss, D.E. Determination of methanesulfonyl fluoride in blood
       matrix with a fluoride ion-selective electrode. Analyst 113, 1485-1486, 1988.
D.E. Moss                         CURRICULUM VITAE                                page 6
Moss, D.E. and Rodriguez, L.A. Alzheimer's dementia: Some recent developments in cholinergic
      pharmacology and a critical review of the cholinergic hypothesis. Texas Medicine 83,
      32-34, 1987 (invited paper)

Moss, D.E. and Rodriguez, L.A. Biological aspects of Alzheimer's disease. The El Paso Physician
      9, 4-8, 1986 (invited paper).

Moss, D.E., Rodriguez, L.A., Herndon, W.C., Vincenti, S.P. and Camarena, M.L. Sulfonyl
      Fluorides as possible therapeutic agents in Alzheimer's Disease: Structure/activity
      relationships as CNS selective cholinesterase inhibitors. In: Alzheimer's and Parkinson's
      Disease: Strategies in Research and Development, A. Fisher, C. Lachman and I. Hanin
      (Eds.). Plenum Press, New York, 1986, pp. 551-556.

Rodriguez, L.A., Moss, D.E., Reyez, E. and Camarena, M.L. Perioral behaviors induced by
       cholinesterase inhibitors: A controversial animal model. Pharmacology Biochemistry and
       Behavior 25, 1217-1221, 1986.

Aston-Jones, G., Rogers, J., Shaver, R.D., Dinan, T.G. and Moss, D.E. Impaired impulse flow
       from nucleus basalis to cortex with age. Nature 318, 462-464, 1985.

Moss, D.E., Rodriguez, L.A. and McMaster, S.B. Comparative behavioral effects of CNS
      cholinesterase inhibitors. Pharmacology Biochemistry and Behavior 22, 479-482, 1985.

Montgomery, S.P., Moss, D.E. and Manderscheid, P.Z. Tetrahydrocannabinol and Levonantradol
      Effects on Extrapyramidal Motor Behaviors: Neuroanatomical Location and Hypothesis of
      Mechanism. In: Marihuana 84, D.J. Harvey and W.D.M. Paton (Eds.). IRL Press; Oxford,
      1985, pp. 295-302.

Moss, D.E., Rodriguez, L.A., Selim, S., Ellett, S.O., Devine, J.V. and Steger, R.W. The Sulfonyl
      Fluorides: CNS Selective Cholinesterase Inhibitors with Potential Value in Alzheimer's
      Disease? Neurology and Neurobiology 18: Senile Dementia of the Alzheimer Type, J.T.
      Hutton and A.D. Kenny (Eds.). Alan R. Liss; New York, 1985, pp. 337-350.

Moss, D.E., Koob, G.F., McMaster, S.B. and Janowsky, D.S. Comparative effects of
      tetrahydrocannabinol on psychostimulant-induced behaviors. Pharmacology Biochemistry
      and Behavior 21, 641-644, 1984.

Moss, D.E., Montgomery, S.P., Salo, A.A. and Steger, R.W. Tetrahydrocannabinol Effects on
      Extrapyramidal Motor Behaviors in an Anmal Model of Parkinson's disease. In: The
      Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects, S. Agurell, W.L.
      Dewey and R. E. Willette (Eds.). Academic Press; New York, l984. pp. 815-828.

Moss, D.E., McMaster, S.B., and Rogers, J. Tetrahydrocannabinol Potentiates reserpine-induced
      hypokinesia. Pharmacology Biochemistry and Behavior 14, 779-783, 1981.
D.E. Moss                          CURRICULUM VITAE                                   page 7

Moss, D.E., Rogers, J.B., Deutsch, J.A., and Salome, R.R. Time dependent changes in anterograde
      scopolamine-induced amnesia in rats. Pharmacology Biochemistry and Behavior 14, 321-
      323, 1981.

Moss, D.E., McMaster, S.B., Castañeda, E., and Johnson, R.L., An automated method for studying
      sterotyped gnawing. Psychopharmacology 69, 267-269, l980.

Moss, D.E. and Johnson, R.L. Tonic analgesic effects of delta-9- tetrahydrocannabinol as measured
      with the formalin test. European Journal of Pharmacology 61, 313-315, 1980.

Moss, D.E. and Fahrney, D. A kinetic analysis of difference in brain acetylcholinesterase from fish
      or mammalian sources. Biochemical Pharmacology 27, 2693-2698, 1978.

Moss, D.E., Peck, P.L., and Salome, R. Tetrahydrocannabinol and acetylcholinesterase.
      Pharmacology Biochemistry and Behavior 8, 763-765, 1978.

Moss, D.E. and Fahrney, D. Anisomycin, acetoxycycloheximide, cycloheximide, and puromycin as
      inhibitors of rat brain acetylcholinesterase in vitro. Journal of Neurochemistry 26,
      1155-1157, 1976.

Avery, D.D., Moss, D.E. and Hendricks, S.A. Food deprivation at weaning and adult behaviors
       elicited by hypothalamic stimulation in the adult rat. Behavioral Biology 16, 155- 160,
       1976.

Moss, D.E. and Rogers, J. Effect of cobra neurotoxin on retention of a brightness discrimination in
      rats. Pharmacology Biochemistry and Behavior 3, 1147-1148, 1975.

Puerto, A., Molina, F., Rogers, J. and Moss, D.E. Physostigmine- induced amnesia for an escape
        response 12 to 72 hours after training. Behavioral Biology 16, 85-90, 1976.

Moss, D.E. and Deutsch, J.A. Review of Cholinergic Mechanisms and Memory. In: Cholinergic
      Mechanisms, P. G. Waser (Ed.). Raven Press; New York, 1975. pp.483-492.

Moss, D.E., Moss, D.R. and Fahrney, D. Puromycin as an inhibitor of rat brain
      acetylcholinesterase. Pharmacology Biochemistry and Behavior 2, 271-275, 1974.

Moss, D.R., Moss, D.E. and Fahrney, D. Puromycin as an inhibitor of acetylcholinesterase.
       Biochimica et Biophysica Acta 350, 95-99, l974.

Bennett, T.L., Hebert, P.J. and Moss, D.E. Hippocampal theta activity and the attention component
       of discrimination learning.. Communications in Behavioral Biology 8, 173-181, 1973.
D.E. Moss                        CURRICULUM VITAE                             page 8
Moss, D.E. and Avery, D.D. An inexpensive, programmable electromechanical commutator.
      Physiology and Behavior 7, 649-651, 1971.

                                        Technical Reports

Moss, D.E. and Keathley, S.J. Pilot study to test sulfonates' ability to provide prophylaxis against
      nerve agents. Final Report, July 1, 1988, to the U.S. Army Medical Research and
      Development Command, Fort Detrick, Frederick, Maryland 21701-5012, on Contract No.
      DAMD17-87-C-7064.

                              Scholarly Presentations and Abstracts

Carcoba Luis Miguel, Sanchez Oscar, Moreno Cesar, Moss D. E., and Rafael Cabeza. In Utero
      Exposure to Methanesulfonyl Fluoride Does Not Alter the Basal Level of Anxiety in
      Rats. Ninth RCMI International Symposium, Baltimore, MD, and the date was Dec. 8 -
      12, 2004.

Carcoba L.M , Sierra G., Sanchez O., Santiago M.l, Cabeza R,l, and Moss D. E. Differential
      Effects of In Utero Exposure to Methanesulfonyl Fluoride On Two Different Spatial
      Memory Tasks. Soc. of Neurosciences, Program No. 436.7, 2004 Abstracts, San Diego,
      November 2004.

Carcoba L.M, Cabeza R ,.Moreno C, Sumaya I.C., Moss D.E Efectos sobre el Sueno de la
      Exposicion in utero a Fluoruro de sulfometano y posterior tratamiento con Δ9 THC.
      Sociedad Mexicana para la Investigacion y Medicina del Sueno, Queretaro, Mexico.
      Second citation: 5o. Congreso Nacional de Sueno, Oct. 2003, Queretaro, Mexico.

Byers, D.M., Moss, D.E., and Irwin, L.N. Prenatal treatment with methanesulfonyl fluoride (MSF):
        Development effects on gene expression associated with sympoms of affective disorder.
       Presented to the 33rd Annual Meeting of the Society for Neuroscience, November 8-12,
       2003, New Orleans, LA. Soc. Neurosci. Abstr. #564.9, 2003.

Favela C.D., Sumaya, I.C., Redding, C., Moss, D.E., and Hohmann, C.F. Effect of
       methanesulfonyl fluoride (MSF) treatment in pregnant rats on offspring development.
       Presented to the 33rd Annual Meeting of the Society for Neuroscience, November 8-12,
       2003, New Orleans, LA. Soc. Neurosci. Abstr. #564.10, 2003.

Borlongan, C.V., Sumaya, I., and Moss, D.E. Pineal gland: A novel tissue source for neural
       transplantation therapy in stroke. Presented to the 32nd Annual Meeting of the Society for
       Neuroscience, November 2-7, 2002, Orlando, FL. Soc. Neurosci. Abstr. #34.11, 2002.

Byers, D.M., Moss, D.E., Irwin, L.N. Global patterns and functional analysis of gene expression in
       Alzheimer's disease. Presented to the 32nd Annual Meeting of the Society for
       Neuroscience, November 2-7, 2002, Orlando, FL. Soc. Neurosci. Abstr. #590.15, 2002.
D.E. Moss                           CURRICULUM VITAE                                   page 9

Sumaya, I.C., Byers, D., Moss, D.E., and Irwin, L. Effect of melatonin on striatial gene expression
      in an animal model of parkinsonism in both the light and the dark phases. Presented to the
      XXXIV Congress of the International Union of Physiological Sciences, August 21-23,
      2002, Adelaide, Australia. Congress of the International Union of Physiological Sciences
      Abstracts, 012.

Borlongan, C.V., Sumaya, I., Moss, D.E., Kumazaki, M., Sakurai, T., Hida, H., and Nishino, H.
       Intracerebral transplantation of melatonin-secreting pineal gland protects against stroke-
       induced deficits in rats. Presented to the 8th International Neural Transplantation and
       Repair Conference, Keystone, Colorado, June 12-16, 2002.

Sumaya, I.C., Byers, D., Moss, D.E., and Irwin, L. Effects of melatonin on rat striatal gene
      expression in an animal model of parkinsonism in the light and dark phase. Presented to the
      31th Annual Meeting of the Society for Neuroscience, November 10-15, 2001, San Diego,
      CA. Soc. Neurosci. Abstr. 27, Abstr. #184.13, 2001.

Cabeza, R.D., Moreno, C., Sumaya, I.C., and Moss, D.E. Effects of in utero exposure to
      methanesulfonyl fluoride on sleep. Presented to the 31th Annual Meeting of the Society for
      Neuroscience, November 10-15, 2001, San Diego, CA. Soc. Neurosci. Abstr. 27, Abstr.
      #846.4, 2001.

Sumaya, I.C., Moss, D.E., and Borlongan, C.V. Melatonin attenuates hypokinesia and reverses
      fluphenazine-induced increase in tyrosine hydroxylase in rat striatum during the light phase.
       Presented to the 30th Annual Meeting of the Society for Neuroscience, November 4-9,
      2000, New Orleans, LA. Soc. Neurosci. Abstr. 26, Abstr. #469.21, Part 1, p. 1266, 2000.

Moss, D.E., Sumaya, I.C., and Borlongan, C.V. Methanesulfonyl fluoride, a highly selective CNS
      inhibitor of acetylcholinesterase, improves passive avoidance performance after ischemia in
      rats. Presented to the 30th Annual Meeting of the Society for Neuroscience, November 4-9,
      2000, New Orleans, LA. Soc. Neurosci. Abstr. 26, Abstr. #860.14, Part 2, p. 2293, 2000.

Moss, D.E. and Berlanga, P. Fluoruro de sulfonilmetano como un tratamiento nuevo para demecia
      seníl tipo Alzheimer. Presented to the "V Reunión Nacional de Asociaciones y Grupos de
      Apoyo de Alzheimer, Monterrey 2000: Un destello de esperanza", May 26 -27, 2000,
      Monterrey, Mexico. (Presented in Spanish)

Moss, D.E., Berlanga, P., Hagan, M.M., Sandoval, H., and Ishida, C. Methanesulfonyl fluoride
      (MSF): A double blind, placebo controlled, cross-over clinical study of safety and efficacy
      in Alzheimer's disease. Presented to the 9th International Behavioral Neuroscience Society
      meeting, April 6-9, 2000, Denver, Colorado. Abstr. Int. Behav. Neurosci. Soc. Vol. 9,
      2000, page 29.
D.E. Moss                          CURRICULUM VITAE                                  page 10
Sumaya, I.C., and Moss, D.E. Melatonin attenuates fluphenazine-induced hypokinesia in young
      and old rats. Presented to the 9th International Behavioral Neuroscience Society meeting,
      April 6-9, 2000, Denver, Colorado. Abstr. Int. Behav. Neurosci. Soc. Vol. 9, p. 38, 2000.

Sumaya, I.C., Moss, D.E., Moreno, C., and Cabeza, R. Effects of acute exogenous melatonin on
      REM and NONREM sleep in rats. Presented to the 29th Annual Meeting of the Society for
      Neuroscience, October 23-28, 1999, Miami Beach, Florida. Soc. Neurosci. Abstr. 25,
      Abstract #460.18, Part 1, p. 1137, 1999.

Cabeza, R., Moreno, C., Moody, J., Mota, A., Reyes-Estrada, L., and Moss, D.E. Effects of the
      acetylcholinesterase inhibitor, methanesulfonyl fluoride, on sleep. Presented to the 29th
      Annual Meeting of the Society for Neuroscience, October 23-28, 1999, Miami Beach,
      Florida. Soc. Neurosci. Abstr. 25, Abstract #857.6, Part 2, p. 2143, 1999.

Moss, D.E., Berlanga, P., Hagan, M.M., Sandoval, H., and Ishida, C. Methanesulfonyl fluoride
      (MSF): A very long acting CNS-selective acetylcholinesterase inhibitor improves senile
      dementia of the Alzheimer type. Pan American Congress on Gerontology and Geriatrics,
      San Antonio, TX, February 20-22, 1999.

Sumaya, I.C., Rienzi, B., Deegan, J., II, Moss, D.E. Light therapy decreases depression and
      increases life satisfaction in institutionalized older adults. Pan American Congress on
      Gerontology and Geriatrics, San Antonio, TX, February 20-22, 1999.

Sumaya, I.C. and Moss, D.E. The effect of melatonin on a fluphenazine-induced hypokinesia in
      young and old rats. Presented to the 28th Annual Meeting of the Society for Neuroscience,
      Los Angeles, CA, November 7-12, 1998. Soc. Neurosci. Abstr. 24, Abstract #48.11, Part I,
      p. 109, 1998.

Moss, D.E., Berlanga, P., Hagan, M.M., Sandoval, H., and Ishida, C. Methanesulfonyl fluoride
      (MSF): A very long acting CNS-selective acetylcholinesterase inhibitor used to treat senile
      dmentia of the Alzheimer type. Presented to the 27th Annual Meeting of the Society for
      Neuroscience, New Orleans, LA, October 25-30, 1997. Soc. Neurosci. Abstr. 23, Abstract
      #20.3, Part I, p. 28, 1997.

Hagan, M.M., Castañeda, E., Fleming, S.M., Galloway, J, and Moss, D.E. Hyperphagia evoked by
       hypothalamic infusion of peptide YY (PYY) is accompanied by increased release of
       acetylcholine (ACh) in the hippocampus. Presented to the 27th Annual Meeting of the
       Society for Neuroscience, New Orleans, LA, October 25-30, 1997. Soc. Neurosci. Abstr.
       23, Abstract #102.36, Part I, p. 256, 1997.

Moss, D.E., Berlanga, P., Hagan, M.M., Sandoval, H., and Ishida, C. Methanesulfonyl fluoride
      (MSF): A double blind, placebo controlled study of safety and efficacy in the treatment of
      senile dementia of the Alzheimer type. Presented to the Alzheimer's Disease International,
      13th International Conference, Helsinki, Finland, September 29-October 1, 1997.
D.E. Moss                          CURRICULUM VITAE                                  page 11

Hagan, M.M., Castañeda, E., Fleming, S.M., and Moss, D.E. Peptide YY (PYY) infusion into the
       hypothalamus alters acetylcholine release in the hippocampus. The Society for the Study of
       Ingestive Behavior, Baltimore, MD, July 1997.

Hagan, M.M. and Moss, D.E. An animal model of conflict associated with choosing highly
       palatable over regular food: Effects of peptide YY. Presented to the 3rd Annual Conference
       of the International Behavioral Neuroscience Society, Clearwater, FL, May 1994.

Hagan, M.M. and Moss, D.E. Differential effects of naloxone, MIF- 1, Tyr-MIF-1, and terbutaline
       on peptide YY-induced hyperphagia. Presented to the 2nd Annual Conference of the
       International Behavioral Neuroscience Society, Clearwater, Florida, April 22-25, 1993.

Hagan, M.M. and Moss, D.E. Naloxone and fluoxetine block eating in a PYY-model of bulimia
       nervosa. Presented to the 22nd Annual Meeting of the Society for Neuroscience, Anaheim,
       CA, October 25-30, 1992. (Soc. Neurosci. Abstr. 18, Abstract #597.7, Part II, p. 1428,
       1992.

Lester, C.C. and Moss, D.E. Effects of clonidine on methylphenidate-induced motor behaviors in
        rats. Presented to the 21st Annual Meeting of the Society for Neuroscience, New Orleans,
        LA, November 10-15, 1991. (Soc. Neurosci. Abstr. 17, Abstract #629.15, Part II, p. 1578,
        1991.)

Moss, D.E. and Pacheco, G. Fluoruro de sulfonil metano: Un inhibidor selectivo para la
      cholinesterasa en el sistema nervosa central ideal para el tratamiento de la enfermedad de
      Alzheimer (Methanesulfonyl fluoride: an ideal central nervous system selective
      cholinesterase inhibitor for the treatment of senile dementia of the Alzheimer type).
      Presented to Santojanni and Ramos Mejia Hospitals in Buenos Aires, Argentina, April 8
      and 9, 1991. (presented in Spanish).

Moss, D.E. Factores Psicologiocos en el Comsumo de Drogas: Applicationes al Proceso Penal
      (Psychological factors in drug abuse: Applications in the Penal System). Presented to the
      Facultad de Derecho de la Universidad Autonoma de Chihuahua, en coordinacion con la
      barra Mexicana, Colegio de abogados de Chihuahua, A.C., Chihuahua, Mexico, September
      19, 20, and 21, 1990. (presented in Spanish).

Moss, D.E., Palacios, R., and Pacheco, G. Methanesulfonyl fluoride: A possible new therapeutic
      agent for the treatment of senile dementia of the Alzheimer type. Presented to the 6th
      International Conference on Alzheimer's Disease International, Mexico City, September
      23-27, 1990.

Moss, D.E. Public policy persepectives on management and care issues in meeting the challenge of
      Alzheimer's disease. Presented to the 6th International Conference on Alzheimer's Disease
      International, Mexico City, September 23-27, 1990.
D.E. Moss                          CURRICULUM VITAE                                 page 12

Hagan, M.M. and Moss, D.E. Food deprivation episodes change the response to opiate agonists
       and eating behavior in an animal model of bulimia and anorexia nervosa. Presented to the
       20th Annual Meeting of the Society for Neuroscience, St. Louis, Missouri, October
       28-November 2, 1990. (Soc. Neurosci. Abstr. 16, Abstr. #318.7, Part I, p. 774, 1990).

Oddie, S.D., Castañeda, E., Moss, D.E., and Whishaw, I. Delta-9- tetrahydrocannabinol does not
       affect efflux of mesotelencephalic dopamine as measured by in vivo microdialysis in freely
       moving rats. Presented to the 20th Annual Meeting of the Society for Neuroscience, St.
       Louis, Missouri, October 28-November 2, 1990. (Soc. Neurosci. Abstr. 16, #450.3, Part II,
       p. 1101, 1990).

Castañeda, E., Moss, D.E., Oddie, S.O., and Whishaw, I.Q. Delta- 9-tetrahydrocannabinol does not
       affect mesotelencephalic levels of extracellular dopamine as measured by in vivo
       microdialysis in freely moving rats. Presented to MARIJUANA '90: An International
       Conference on Cannabis and Cannabinoids held at the Orthodox Academy of Crete,
       Kolympari, Chania, Greece, July 8-11, 1990.

Moss, D.E. Competitive vs. noncompetitive acetylcholinesterase inhibitors. Presented to Next
      Generation Tacrine: Cognitive Activators Discovery (Symposium sponsored by
      Parke-Davis), Ypsilanti, Michigan, March 15-16, 1990.

Moss, D.E., Wong, D., Enriquez, A., Sands, S.F., and Whitworth, R.H. Arylesterase and
      paraoxonase levels in suspected Alzheimer patients and age matched controls. Presented to
      the Society for Neuroscience, November 1989, Phoenix, Arizona. (Soc. Neurosci. Abstr.
      15, Abst. #262.6, 1989).

Moss, D.E. (Invited Speaker) Animal Models of Alzheimer's Disease. Presented to the Société de
      Pharmacologie Experimentale "Approche Expérimentale et Clinique de la Maladie
      D'Alzheimer", Paris 14eme, France, May 1989.

Moss, D.E. Smokers, jokers, and midnight tokers: do nicotine and marijuana have a common
      mode of action? Colloquium presented to the Department of Biology, Texas Woman's
      University, Denton, Texas, January 26, 1989.

Moss, D.E., Manderscheid, P.Z., Norman, A.B., and Sanberg, P.R. Cannabinoid potentiation of
      neuroleptic-induced hypokinesia: The nicotinic hypothesis of action. Presented to the
      Society for Neuroscience, November 1988, Toronto, Canada. (Soc. Neurosci. Abstr. 14,
      #505.1, p. 1257, 1988).

Manderscheid, P.Z., Sanberg, P.R., Norman, A.B., Fogelson, H.M., McConville, B.J., and Moss,
      D.E. Nicotine markedly potentiates neuroleptic-induced catalepsy. Presented to the
      Society for Neuroscience, November 1988, Toronto, Canada. (Soc. Neurosci. Abstr. 14,
      #505.2, p. 1257, 1988).
D.E. Moss                          CURRICULUM VITAE                                 page 13

Yusuf, N.L., Sands, S.F., and Moss, D.E. Scopolamine induced visual memory deficits in rhesus
       monkeys. Presented to the Society for Neuroscience, November 1988, Toronto, Canada.
       (Soc. Neurosci. Abstr. 14, #455.2, p. 1135, 1988).

Moss, D.E. (Invited Speaker) Sulfonyl Fluorides as Therapeutic Agents in Alzheimer's Disease.
      Presented to "Advances in Alzheimer's Therapy: Cholinesterase Inhibitors", a World
      Federation Neurology Research Group on Dementias Symposium, March 19-20, 1988,
      Springfield, Illinois.

Moss, D.E. (Invited Speaker) Getting gray, getting bald, losing your mind: current perspectives on
      treating Alzheimer's disease. Presented to the annual neuroscience retreat of the Center for
      Neuroscience of the University of Pittsburg, September 18, 1988, Oglebay Park, West
      Virginia.

Nakano, T., Kobayashi, H., Moss, D.E., and Yuyama, A. Effects of two irreversible
      anticholinesterases on the central cholinergic system of mice. Presented to the 61st General
      Meeting of the Japanese Pharmacological Society, March 23- 26, 1988, Fukuoka, Japan
      (The Japanese Journal of Pharmacology 46, #O-35, p. 57P).

Moss, D.E. Sulfonyl fluorides: novel CNS selective cholinesterase inhibitors with potential value
      for treating Alzheimer's disease. Colloquium presented to the Neuroscience Seminar Series
      and the Department of Psychiatry, University of Cincinnati, March 17, 1988.

Moss, D.E., Manderscheid, P.Z., Palacios, R., and Perez, R.G. Methanesulfonyl fluoride: An
      active CNS cholinesterase inhibitor in primates. Presented to the Society for Neuroscience,
      November 16-21, 1987, New Orleans, LA (Soc. Neurosci. Abstr. 13, Part 2, #286.11, p.
      1028).

Moss, D.E. (Chairman of the Session on Neuropharmacology of Cannabinoids), Manderscheid,
      P.Z., Kobayashi, H. and Montgomery, S.P. Extrapyramidal Effects of Cannabinoids: Motor
      Behaviors. Invited paper presented to Marihuana '87, an international symposium on
      marihuana and cannabinoids, September 2-5, 1987, Melbourne, Australia.

Manderscheid, P.Z., Moss, D.E., Kobayashi, H. and Montgomery, S.P. Nicotinic Cholinergic
      Effects of Cannabinoids in the Extrapyramidal System. Presented to Marihuana '87, an
      international symposium on marihuana and cannabinoids, September 2-5, 1987, Melbourne,
      Australia.

Moss, D.E., Gutierrez, Y., Perez, R.G. and Kobayashi, H. Methanesulfonyl Fluoride: A Novel
      CNS Selective Cholinesterase Inhibitor with Potential Value in Treating Dementia of the
      Alzheimer Type? Presented to the Xth International Congress of Pharmacology, August
      23-28, 1987, Sydney, Australia.
D.E. Moss                          CURRICULUM VITAE                                page 14
Moss, D.E., Keathley, S.J. and Gutierrez, Y. Sulfonyl Fluorides: Novel CNS Selective
      Cholinesterase Inhibitors. Presented to the Sixth Medical Chemical Defense Bioscience
      Review, Johns Hopkins University, Columbia, Maryland, August 4-7, 1987.

Kobayashi, H., Moss, D.E. and Manderscheid, P.Z. Effect of Tetrahydrocannabinol on
      Hypokinesia Induced by Fluphenazine.     Presented to the 60th General Meeting of the
      Japanese Pharmacology Society Annual Meeting, March, 1987, Chiba, Japan. The
      Japanese Journal of Pharmacology 43, Suppl. 221P, Abst. P-133.

Moss, D.E. Alzheimer's Dementia: Some Recent Developments in Cholinergic Pharmacology and
      a Critical Review of the Cholinergic Hypothesis. An invited paper presented to Alzheimer's
      Disease: Biological and Psychological Issues, a conference held at the University of Texas
      at Austin November 12, 1986.

Moss, D.E., Montgomery, S.P., Manderscheid, P.Z., and Kobayashi, H. CNS Effects of
      Cannabinoids: A Key to Understanding Marijuana. Presented to the Twenty-seventh
      Annual Meeting of the Psychonomic Society, New Orleans, Louisiana, November 13, 1986.


Rodriguez, L.A., Moss, D.E. and Camarena, M.L. Sulfonyl Fluorides: A Structure/Activity Study
       as CNS Selective Cholinesterase Inhibitors. Presented to the Society for Neuroscience
       Annual Meeting, October 20-25, 1985, Dallas, Texas (Soc. Neurosci. Abstr. 11, p. 189,
       #60.21).

Moss, D.E. Extrapyramidal Motor Effects of THC: Evidence for a specific nondopaminergic
      neurotransmitter effect. Invited address entitled "Mechanisms of Central Actions of
      Cannabinoids" delivered to the American Society for Pharmacology and Experimental
      Therapeutics and the American Chemical Society, Division of Medicinal Chemistry,
      August 18-22, 1985, Boston, Massachusetts.

Moss, D.E. Sulfonyl Fluorides: CNS Selective Cholinesterase Inhibitors. Presented to the 30th
      OHOLO Biological Conference "Basic and Therapeutic Strategies in Alzheimer's and Other
      Age-Related Neuropsychiatric Disorders", Eilat, Israel, March 24-27, 1985.

Moss, D.E. Sulfonyl Fluorides: CNS Selective Cholinesterase Inhibitors. Presented to the
      Departments of Physiology and Pharmacology, University of New Mexico, Albuquerque,
      New Mexico, March 19, 1985.

Moss, D.E. Sulfonyl Fluorides: Novel Organ Selective Cholinesterase Inhibitors. Presented to the
      Institute of Chemical Defense, United States Army, Aberdeen Proving Ground, Maryland,
      February 27, 1985.

Moss, D.E. Development of CNS Selective Cholinesterase Inhibitors: Phenylmethanesulfonyl
      Fluoride. Presented to the Fifth Tarbox Parkinson's Disease Symposium: The Norman
D.E. Moss                      CURRICULUM VITAE                                page 15
      Rockwell Conference on Alzheimer's Disease, Texas Tech University School of Medicine,
      October 18, 1984.

Moss, D.E., Montgomery, S.P. and Manderscheid, P.Z. Tetrahydrocannabinol and levonantradol
      effects on extrapyramidal motor behaviors: neuroanatomical location and hypothesis of
      mechanism. Presented to the 9th International Congress of Pharmacology, 3rd Sattelite
      Symposium on Marihuana, Marihuana '84, in Oxford, England, August, 1984.

Rodriguez, L.A., Moss, D.E. and Camarena, M.L. Phenylmethane- sulfonyl Fluoride and
       Methanesulfonyl Fluoride: CNS Selective Cholinesterase Inhibitors. Presented to the
       Society for Neuroscience Annual Meeting, Anaheim, California, October 10-15, 1984.
       (Soc. Neurosci. Abst., 10, # 9.11, p. 18).

Montgomery, S.P. and Moss, D.E. Nicotine Mimics Tetrahydrocannabinol and Levonantradol
      Potentiation of Reserpine- Induced Hypokinesia. Presented to the Society for Neuroscience
      Annual Meeting, Boston, Massachusetts, November 6-11, 1983. (Soc. Neurosci. Abst. 9,
      #331.1).

Rogers, J., Aston-Jones, G., Dinan, T., Shaver, R. and Moss, D.E. Conduction Velocity of
       Cortically-Projecting Nucleus Basalis Neurons Decreases with Age. Presented to the
       Society for Neuroscience Annual Meeting, Boston, Massachusetts, November 6-11, 1983.
       (Soc. Neurosci. Abst. 9, #271.9)

Moss, D.E. Effects of Cannabinoids on Extrapyramidal Motor Behaviors: Theoretical and Clinical
      Implications. Presented to the Addiction Research Foundation and the Department of
      Psychology, University of Toronto, Toronto, Canada, October 27, 1983.

Moss, D.E. Correlatos Bioquimicos de la Psicosis. Presented to La Escuela Libre de la Psicologia,
      Universidad de Chihuahua, Chihuahua, Mexico, March l7 and l8, l983. (Presented in
      Spanish).

Moss, D.E., McMaster, S.B., Koob, G. and Montgomery, S. Tetrahydrocannabinol Effects on
      Extrapyramidal Behaviors: Interactions with Pychoactive Drugs. Presented to the Society
      for Neuroscience, November, l982, Minneapolis, Minnesota. (Soc. Neurosci. Abst. 8,
      #290.4).

Moss, D.E., Montgomery, S.P., Salo, A. and Steger, R. Tetrahydrocannabinol Effects on
      Extrapyramidal Motor Behaviors: A Study of Drug Interactions. Presented to
      Cannabinoids 82, an international conference on cannabinoids, August, l982, Louisville,
      Kentucky.

Moss, D.E., Rodriguez, L.A., Devine, J.V. and Ellett, S. Selective Inhibition of Central
      Cholinesterase In Vivo. Presented to the American Society for Pharmacology and
D.E. Moss                        CURRICULUM VITAE                                page 16
      Experimental Therapeutics and the Society of Toxicology, August l982, Louisville,
      Kentucky. (Abstract reprinted in The Pharmacologist 24, No. 3, l982).

Moss, D.E. Tetrahydrocannabinol/Reserpine Akinesia: A Key to an Enigma. Invited colloquium
      presented to the Department of Biological psychology and Psychiatry, University of
      Oklahoma Health Science Center, September l98l, Oklahoma City, Oklahoma.

Moss, D.E. Extrapyramidal Effects of Tetrahydrocannabinol: Interactions with Reserpine. Invited
      colloquium presented to the Chemistry and Behavior Program, Department of Psychology,
      Texas Christian University, September, l98l, Fort Worth, Texas.

Moss, D.E. Interaction of Tetrahydrocannabinol with Psychoactive Drugs: Practical and
      Theoretical Considerations. Invited colloquium presented to the Division of Life Sciences,
      University of Texas at San Antonio, February, l982, San Antonio, Texas.

Moss, D.E., McMaster, S.B., and Salo, A.A. Marijuana: Practical and Theoretical Considerations.
       Invited address given to the Fourth Annual Meeting of the El Paso Psychological
      Association and Psicologia Norteamericana e Interamericana, March l982, El Paso, Texas.

Moss, D.E. Tetrahydrocannabinol/Reserpine akinesia: A Key to an Enigma. Invited colloquium
      presented to the Departments of Pharmacology and Obstetrics/Gynecology, University of
      Texas Health Science Center at San Antonio, December, l98l, San Antonio, Texas.

Moss, D.E. Interactions Between Tetrahydrocannabinol (Marijuana) and other Psychoactive
      Drugs: Practical and Theoretical Implications. Invited colloquium presented to the Grand
      Rounds, Texas Tech School of Medicine Regional Health Science Center, April, l982, El
      Paso, Texas.

Moss, D.E., McMaster, S.B. and Koob, G. Tetrahydrocannabinol Effects on Extrapyramidal Motor
      Behaviors: A Key to an Enigma. Presented to the Southwestern and Rocky Mountain
      Divisions of the American Association for the Advancement of Science and the New
      Mexico Academy of Science, April, l982, El Paso, Texas. (New Mexico Journal of
      Science, Vol. 22 (1), Abstr. #l07, l982).

Moss, D.E., Deyo, S.N., Rogers, J., and McMaster, S.B. Tetrahydrocannabinol Potentiation of
      Reserpine-Induced Catalepsy. Presented to the Society for Neuroscience, October 1981,
      Los Angeles, California. (Soc. Neurosci. Abstr. 7, #223.16, 1981).

Moss, D.E., Rogers, J.B., Peck, P.L., Salome, R.R., and Hall, E. Scopolamine Effects on Learning
      and Retention Performance in Rats. Presented to the Society for Neuroscience, November
      1979, Atlanta, Georgia. (Soc. Neurosci. Abstr. 5, #1058, 1979).
D.E. Moss                         CURRICULUM VITAE                             page 17
Moss, D.E. (Session Chairman) and Deutsch, J.A. Review of Cholinergic Mechanisms and
      Memory. Presented to the International Symposium on Cholinergic Mechanisms, March
      1974, Boldern, Switzerland.

Moss, D.E. Effects of Biogenic Amines on Acetylcholinesterase. Presented to Southwestern
      Psychological Association, May 1976, Albuquerque, New Mexico.

Moss, D.E. and Fahrney, D. Inhibition of Acetylcholinesterase by Antibiotics used in Memory
      Experiments. Presented to the Rocky Mountain Psychological Association, May 1976,
      Phoenix, Arizona.

Moss, D.E. and Avery, D.D. Puromycin and Cholinergic Neurotransmission: A Possible
      Mechanism of Memory Interference. Presented to the Rocky Mountian Psychological
      Association, May 1973, Las Vegas, Nevada.

Moss, D.E. and Avery, D.D. Food Deprivation at Weaning and Adult Behaviors Elicited by
      Hypothalamic Stimulation in the Adult Rat. Presented to the Rocky Mountain
      Psychological Association, May 1972, Albuquerque, New Mexico.

Moss, D.E., Moss, D.R. and Fahrney, D. Puromycin as a Pachycurare-like Inhibitor of
      Acetylcholinesterase. Preseted to the Southwestern and Rocky Mountain Divisions of the
      American Association for the Advancement of Science, April 1972, Fort Collins, Colorado.

Moss, D.E. and Avery, D.D. The Effects of Intrahippocampal Injections of Puromycin on
      Retention Performance in an Aversive Discrimination Task. Presented to the Rocky
      Mountain Psychological Association, May 1971, Denver, Colorado.



                                  Current Research Interests

   Research areas of primary interest are neurochemical and neuropharmacological investigations
into the basis of brain function and behaviors. Particular areas of interest include the
cholinergic system in learning and memory and changes in those systems that may be responsible
for memory deterioration and dementia in brain disorders associated with aging, particularly
Alzheimer's disease and related dementing disorders. The development of therapeutic drugs, drug
design, and behavioral evaluation of the efficacy of drugs are the objectives of this research
program. A new direction in my research interests is neuroprotection against and treatment of
syndromes related to ischemia, trauma, and other brain insults.


                                    Professional References

Dr. Joseph Rogers, Director                         Dr. Louis Irwin, Chairman
D.E. Moss                        CURRICULUM VITAE                          page 18
Sun Health Research Institute               Department of Biological Sciences
10515 W. Santa Fe Drive                     University of Texas at El Paso
Sun City, AZ 85351                          El Paso, TX 79968
(602) 876-5467                              (915) 747-6983

Dr. Judith Goggin, Chairman
Department of Psychology
University of Texas at El Paso
El Paso, TX 79968
(915) 747-6564

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:19
posted:1/15/2011
language:English
pages:18